Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus
Lunai Bioworks Inc. has wrapped up a $20 million preferred-stock deal, securing CNS drug-delivery and neurotherapeutic IP in an effort to broaden its brain-disease lineup. The move, finalized May 1, also bolsters its case for Nasdaq equity compliance. Lunai disclosed the acquisition Monday.